Cytotoxicity effect of trastuzumab on canine peripheral blood mononuclear cells

Document Type : Full paper (Original article)

Authors

1 Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Tokyo, 183-0054, Japan

2 Laboratory of Small Animal Surgery 2, School of Veterinary Medicine, Kitasato University, Aomori, 034-8628, Japan

Abstract

Background: Trastuzumab is an antibody drug used to treat human epidermal growth factor receptor 2 (HER2) overexpressing human metastatic breast cancer. Antibody-dependent cellular cytotoxicity (ADCC) is considered to be the major mechanism of cytotoxicity of the drug. However, its ability to induce an ADCC response in canine peripheral blood mononuclear cells (PBMCs) is not well established. Aims: We aimed to evaluate the ability of trastuzumab in enhancing the cytotoxicity of PBMCs against canine tumor cells. Methods: We used canine tumor cell lines isolated from metastatic mammary gland tumors (CHMm and CIPm) and thyroid adenocarcinoma (CTAC). The binding of trastuzumab to the cells was confirmed using flow cytometry analysis. Peripheral blood mononuclear cells obtained from healthy beagles and lymphokine-activated killer (LAK) cells, generated by interleukin-2 (IL-2) stimulation of PBMCs, were used as effector cells. Standard lactate dehydrogenase (LDH) release assay was used to measure the cytotoxicity of the LAK cells against tumor cell lines in the presence of trastuzumab. Results: Trastuzumab enhanced the cytotoxicity of PBMCs against CHMm. Moreover, LAK cells killed CHMm synergistically in the presence of trastuzumab. However, the presence of trastuzumab did not produce such a synergistic effect when LAK cells acted against CIPm and CTAC. Conclusion: We confirmed the ability of trastuzumab to induce an ADCC response in canine PBMCs and determined its synergistic effect with LAK cells. Although the in vitro system in the present study did not show the induction of trastuzumab-mediated ADCC response against all canine tumor cell lines, the results of this study indicate the potential antitumor activity of trastuzumab in canines.

Keywords

Main Subjects

References

Carter, P; Presta, L; Gorman, CM; Ridgway, JB; Henner, D; Wong, WL; Rowland, AM; Kotts, C; Carver, ME and Shepard, HM (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U. S. A., 89: 4285-4289.
Clynes, RA; Towers, TL; Presta, LG and Ravetch, JV (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med., 6: 443-446.
Collins, DM; O’Donovan, N; McGowan, PM; O’Sullivan, F; Duffy, MJ and Crown, J (2012). Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann. Oncol., 23: 1788-1795.
Cooley, S; Burns, LJ; Repka, T and Miller, JS (1999). Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp. Hematol., 27: 1533-1541.
Cuello, M; Ettenberg, SA; Clark, A; Keane, MM; Posner, RH; Nau, MM; Dennis, PA and Lipkowitz, S (2001). Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res., 61: 4892-4900.
Grimm, EA; Mazumder, A; Zhang, HZ and Rosenberg, SA (1982). Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med., 155: 1823-1841.
Kawaguchi, Y; Kono, K; Mizukami, Y; Mimura, K and Fujii, H (2009). Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme. Anticancer Res., 29: 2137-2146.
Kim, Y; Lee, SH; Kim, CJ; Lee, JJ; Yu, D; Ahn, S; Shin, DJ and Kim, SK (2019). Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody coated tumor cells. BMC. Vet. Res., 15: 339.
Lin, YC; Huang, YC; Wang, YS; Juang, RH; Liao, KW and Chu, RM (2010). Canine CD8 T cells showing NK cytotoxic activity express mRNAs for NK cell-associated surface molecules. Vet. Immunol. Immunopathol., 133: 144-153.
London, CA (2013). Signal transduction and cancer. In: Withrow, SJ; Vail, DM and Page, RL (Eds.), Withrow and MacEwen’s small animal clinical oncology. (5th Edn.), Missouri, Elsevier. PP: 221-229.
Meropol, NJ; Barresi, GM; Fehniger, TA; Hitt, J; Franklin, M and Caligiuri, MA (1998). Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate dose-pulsing. Cancer Immunol. Immunother., 46: 318-326.
Mimura, K; Kono, K; Hanawa, M; Kanzaki, M; Nakao, A; Ooi, A and Fujii, H (2005). Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin. Cancer Res., 11: 4898-4904.
Nakagawa, T; Watanabe, M; Ohashi, E; Uyama, R; Takauji, S; Mochizuki, M; Nishimura, R; Ogawa, H; Sugano, S and Sasaki, N (2006). Cyclopedic protein expression analysis of cultured canine mammary gland adenocarcinoma cells from six tumours. Res. Vet. Sci., 80: 317-323.
Ohnishi, H; Okuno, K and Yasutomi, M (1993). Successful in vivo generation of canine lymphokine-activated killer cells by continuous recombinant interleukin-2 infusion through the splenic artery. Cancer Biother., 8: 213-222.
Pena, L; Gama, A; Goldschmidt, MH; Abadie, J; Benazzi, C; Castagnaro, M; Diez, L; Gartner, F; Hellmen, E; Kiupel, M; Millan, Y; Miller, MA; Nguyen, F; Poli, A; Sarli, G; Zappulli, V and Mulas, JM (2014). Canine mammary tumors: a review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry. Vet. Pathol., 51: 127-145.
Singer, J; Weichselbaumer, M; Stockner, T; Mechtcheriakova, D; Sobanov, Y; Bajna, E; Wrba, F; Horvat, R; Thalhammer, JG; Willmannb, M and Jarolim, EJ (2012). Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol. Immunol., 50: 200-209.
Slamon, DJ; Godolphin, W; Jones, LA; Holt, JA; Wong, SG; Keith, DE; Levin, WJ; Stuart, SG; Udove, J and Ullrich, A (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244: 707-712.
Slamon, DJ; Leyland-Jones, B; Shak, S; Fuchs, H; Paton, V; Bajamonde, A; Fleming, T; Eiermann, W; Wolter, J; Pegram, M; Baselga, J and Norton, L (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N. Engl. J. Med., 344: 783-792.
Sliwkowski, MX; Lofgren, JA; Lewis, GD; Hotaling, TE; Fendly, BM and Fox, JA (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol., 26: 60-70.
Takehana, T; Kunitomo, K; Kono, K; Kitahara, F; Iizuka, H; Matsumoto, Y; Fujino, MA and Ooi, A (2002). Status of c-erbB-2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int. J. Cancer. 98: 833-837.
Veloso, ES; Gonçalves, INN; Silveira, TL; Oliveira, FS; Vieira, DS; Cassali, GD; Puerto, HLD and Ferreira, E (2020). Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas. BMC. Vet. Res., 16: 24.
Yamaguchi, Y; Hironaka, K; Okawaki, M; Okita, R; Matsuura, K; Ohshita, A and Toge, T (2005). HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab. Anticancer Res., 25: 827-832.
Yoshimoto, S; Kato, D; Kamoto, S; Yamamoto, K; Tsuboi, M; Shinada, M; Ikeda, N; Tanaka, Y; Yoshitake, R; Eto, S; Saeki, K; Chambers, JK; Kinoshita, R; Uchida, K; Nishimura, R and Nakagawa, T (2019). Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma. J. Vet. Med. Sci., 81: 1034-1039.

Files

Share

How to cite

Statistics